Intervention 2: Aflibercept

PreclinicalProtein / enzyme

Intervention 2: Aflibercept is one of 28 small molecule programs targeting Diabetic Macular Edema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Macular EdemaActive, not recruiting

Diabetic Macular EdemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Diabetic Macular Edema

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

53 2

Vabysmo

Roche

Approved

12 3

Beovu

Novartis

Approved

6 4

Decadron

AAspen Global Incorporated

Approved

13 5

Amaryl

Sanofi

Approved

1 6

Aldactone

Pfizer

Approved

1 7

Kenalog

BBassett Healthcare

Approved

4 8

Klor-Con

Jardiance

1 10

Farxiga

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Macular Edema1 trial

Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema

Completed·—·N/A·NCT07096713·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intervention 2: Aflibercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention 2: Aflibercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention 2: Aflibercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Benha University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: BBenha University

Intervention 2: Aflibercept

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News